GLP-1 Weight Loss Meds: Questions to Ask a Clinician

Roughly 18% of U.S. adults report having tried a GLP-1 medication for weight loss or diabetes management, according to a 2026 overview of the drug class. That level of adoption means most primary care visits about weight now involve some version of the same conversation, and the quality of that conversation depends heavily on what the patient brings to it.

The most productive appointments cover five territories: candidacy and health history, contraindications and family history, baseline labs and current medications, cost and coverage, and the long-term plan for side effects, muscle preservation, and what happens after weight loss stabilizes. Patients who arrive with written questions in those areas tend to leave with a clearer treatment plan than those who open with a single request for a prescription.

GLP-1 therapy sits in a category where the decision is medical, not consumer. A clinician evaluating a patient for these drugs is screening for pancreatitis history, thyroid cancer risk, and interactions with existing medications, all of which shape whether treatment is appropriate and which option makes sense.

Key Takeaways

• Candidacy hinges on BMI, related conditions, personal and family medical history, and a review of every current medication.
• Semaglutide and tirzepatide differ in mechanism, brand labeling, and coverage, so the comparison belongs in the appointment.
• Muscle preservation, nausea management, and a plan for maintenance or weight regain should be discussed before the first dose, not after.

Questions to Ask Before You Start

Candidacy for GLP-1-class treatment rests on measurable criteria a clinician can review in one visit: BMI, weight-related conditions, personal and family history, baseline lab values, and the full list of medications and supplements a patient already takes. Screening also covers pregnancy plans, breastfeeding status, and mental health history, since each changes the risk calculation.

Am I a Candidate Based on My BMI, Health History, and Goals?

Clinicians typically evaluate candidacy around a BMI of 30 or higher, or a BMI of 27 and above paired with a weight-related condition. Per answers from a board-certified physician nutrition specialist, those associated conditions include high blood pressure, high cholesterol, and fatty liver, and coverage decisions often track the same thresholds.

Useful questions here:

• Where does my BMI fall, and do I have conditions that change my eligibility?
• Does my type 2 diabetes, prediabetes, hypertension, sleep apnea, or kidney disease affect which approach is appropriate?
• What weight or health outcome would we consider a successful response, and by when would we evaluate it?
• How do my personal goals fit against what the medication realistically does?

Waist circumference also enters the assessment. Patients carrying visceral fat with a waist above 35 inches for women or 40 inches for men may warrant closer evaluation even at a lower BMI.

What Conditions or Family History Could Make Treatment Unsafe?

Some histories rule GLP-1 therapy out. A personal or family history of medullary thyroid cancer, or of multiple endocrine neoplasia syndrome type 2 (MEN2), is a contraindication that a clinician screens for directly.

Other conditions call for caution rather than exclusion. Prior pancreatitis, gastroparesis, and diabetic eye disease all require a specific risk discussion, and patients with very low muscle mass or low bone density need closer monitoring if treatment proceeds.

Worth asking:

• Does anyone in my family have thyroid cancer, and does the type matter?
• Given my history of gallbladder problems, pancreatitis, or digestive issues, what changes?
• Which of my conditions makes this riskier, and how would we watch for problems?

Which Baseline Tests and Medication Reviews Do I Need?

Baseline testing gives a reference point for later comparison. Ask whether a comprehensive metabolic panel, lipid panel, A1C or fasting blood sugar, thyroid testing, and kidney function labs will be drawn before the first dose, and how frequently they will be repeated.

The medication review is equally consequential. Bring every prescription, over-the-counter product, and supplement, including oral contraceptives, blood pressure drugs, insulin, and sulfonylureas, since slowed gastric emptying and improved blood sugar control can require dose adjustments made by the prescriber.

Questions to raise:

• Which labs do we need now, and what values would concern you later?
• Do any of my current medications need adjusting, and who makes that call?
• Will you track body composition or waist measurements alongside weight?

How Could Pregnancy, Breastfeeding, or Mental Health Affect the Decision?

Pregnancy and breastfeeding change the conversation entirely. Patients who are pregnant, trying to conceive, or nursing should ask directly about the labeling and about how far in advance of a planned pregnancy the medication would need to stop, a decision the prescriber makes.

Mental health history belongs on the table too. A history of eating disorders, active depression, or anxiety warrants explicit discussion, because appetite suppression interacts with restrictive eating patterns in ways that need monitoring. Patients in addiction recovery may also want to review how reduced food noise affects other cravings, a topic covered in guidance for patients on GLP-1s in recovery.

Ask who on the care team will follow mood and eating behavior over time, and what symptoms should prompt a call between visits.

Choosing a Medication and Paying for Care

Option selection turns on two questions: which molecule and formulation matches the patient's medical picture, and what the treatment will cost once insurance rules are applied. Semaglutide and tirzepatide dominate the conversation, though liraglutide and oral formulations remain relevant for specific situations, and coverage rules frequently determine the practical answer.

Which GLP-1-Class Option Fits My Health Needs?

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after eating, and they act on the GLP-1 receptor to reduce appetite, slow stomach emptying, and improve blood sugar control. Which of these drugs a clinician selects depends on whether type 2 diabetes is present, what the patient's insurance covers, and tolerance history.

The brand and indication distinctions matter for coverage:

	Semaglutide	Tirzepatide	Liraglutide
Weight-loss brand	Wegovy	Zepbound	Saxenda
Diabetes brand	Ozempic, Rybelsus (oral)	Mounjaro	Victoza
Receptors targeted	GLP-1	GLP-1 and GIP	GLP-1
Injection frequency	Weekly	Weekly	Daily

Questions to bring: Which of these does my plan cover, and does my diabetes status change which one you would prescribe?

What Is the Difference Between Semaglutide and Tirzepatide?

Tirzepatide acts on both the GLP-1 receptor and GIP, while semaglutide targets GLP-1 alone. That dual mechanism has been associated with stronger blood sugar and weight outcomes in trials, though individual response and side effect tolerance vary enough that the choice is clinical.

Average weight loss across this drug class runs from 5.3% to 17.8% of body weight, with some patients exceeding 30%, figures comparable to bariatric surgery outcomes in a subset of cases. Ask what range applies to the specific medication under discussion and what would count as a non-response.

What Should I Ask About Injections, Pills, and Dose Escalation?

Most GLP-1 options are weekly or daily subcutaneous injections; Rybelsus is an oral semaglutide tablet with its own administration requirements. Ask for a demonstration of injection technique, storage rules, and what to do about a missed dose, all of which the prescriber or pharmacist should walk through directly.

Dose escalation follows a manufacturer schedule, and clinicians vary in how aggressively they advance it. Some prescribers hold patients at the lowest effective dose and increase only when weight loss slows, an approach that reduces gastrointestinal side effects.

Ask how your prescriber approaches escalation and who to contact if a dose increase produces intolerable symptoms.

Will Insurance Coverage, Prior Authorization, or Savings Programs Affect My Options?

Coverage determines the practical option set more often than clinical preference does. Ask whether the clinic files prior authorization requests, what documentation the plan requires, how long approval takes, and what the appeal process looks like if the request is denied, a process detailed in an insurance and coverage guide for this drug class.

Specific questions to ask the office:

• What is my out-of-pocket cost with and without coverage?
• Does my plan require documented lifestyle intervention or a step therapy trial first?
• Am I eligible for a manufacturer savings card, and does my plan type disqualify me?
• What happens to my cost if my employer drops coverage mid-treatment?

Medicare, Medicaid, and commercial plans apply different rules, and employer formularies change annually. Ask what the cash price would be as a fallback figure.

What Should I Know Before Considering Telehealth or Compounded Medication?

Telehealth platforms including Ro have expanded access, and the questions to ask them mirror what a patient would ask an in-person clinic: who is the prescribing clinician, what is their license and specialty, how are baseline labs obtained, and what happens if a serious side effect appears at 9 p.m. on a Saturday.

Compounded GLP-1 medications from compounding pharmacies are not FDA-approved products and are not evaluated for safety, effectiveness, or quality the way branded drugs are. Ask which pharmacy compounds the formulation, what the concentration is, whether the product contains salt forms or additives, and how the platform handles adverse events. A side-by-side look at telehealth GLP-1 programs is worth reviewing before committing to a subscription.

Ask also whether the program includes clinician follow-up or only medication shipment.

Planning for Side Effects, Lifestyle, and Long-Term Care

Side effects concentrate at the start of treatment and after each dose increase, and most are gastrointestinal. The longer-term issues are different: muscle loss can account for up to 20% of total weight lost, and weight regain after stopping is common enough that clinicians treat obesity as a chronic condition requiring an ongoing plan.

Which Side Effects Are Common, and How Will We Manage Them?

Nausea, vomiting, diarrhea, and constipation are the most frequent complaints, appearing most often when starting the medication or increasing the dose. Bloating, abdominal pain, reflux, fatigue, headache, burping, and hair loss also show up, along with dehydration, since these drugs reduce thirst and increase sodium and water loss through the kidneys.

Practical management approaches a clinician can outline include eating smaller and more frequent meals, avoiding skipping breakfast, limiting fatty and very high-fiber meals during symptomatic days, and building fluid and fiber intake gradually. Prescription anti-nausea medication is an option some clinicians add.

Ask what to do at home, what the office can prescribe, and at what point symptoms warrant pausing treatment, a decision for the prescriber rather than the patient.

Which Symptoms Are Red Flags That Need Prompt Medical Attention?

Certain symptoms require contacting a clinician promptly rather than waiting for the next appointment. Severe or persistent abdominal pain, especially pain radiating to the back with vomiting, can indicate pancreatitis or gallstones and needs same-day evaluation.

Other red flags to confirm with the prescriber:

• Vomiting that prevents keeping fluids down, or signs of dehydration
• Signs of hypoglycemia, particularly for patients also taking insulin or sulfonylureas
• Rash, swelling, or breathing difficulty suggesting an allergic reaction
• A significant, sustained change in resting heart rate (this drug class raises resting heart rate by an average of two to five beats per minute, so larger shifts warrant a call)
• Vision changes in patients with diabetic eye disease

Ask for a written list of after-hours contact instructions and which symptoms justify an emergency department visit.

How Should I Protect Muscle and Nutrition During Weight Loss?

Muscle loss during GLP-1 treatment can reach up to 20% of total weight lost, driven by rapid weight reduction and sharply reduced appetite. It affects men more than women, and strength training two to three times per week alongside adequate protein intake offsets a meaningful share of it.

Many prescribers target roughly 80 to 120 grams of protein daily, with taller and more active patients toward the high end. Protein at breakfast and after workouts carries particular weight, and protein shakes or Greek yogurt work when appetite makes solid food difficult.

Nutrient deficiencies are common given food intake reductions of 16% to 39%, which is why a referral to a registered dietitian nutritionist and periodic body composition testing are reasonable requests. Rapid loss exceeding 14% of total body weight in three to four months has been linked to significant bone loss, so ask how quickly loss should be occurring and whether bone density screening applies.

What Lifestyle Changes Will Support Metabolic Health?

Resistance training and protein intake anchor the plan, and aerobic activity, sleep, and hydration fill it out. Ask the clinician for a specific weekly activity target and whether physical therapy or supervised exercise is appropriate given joint pain or mobility limits.

Appetite suppression creates a window where habit change is easier, and clinicians who work in obesity medicine often use it deliberately: meal structure, grocery patterns, and eating pace built during the first year tend to hold better afterward. Reduced food noise makes those changes feel less effortful while medication is active.

Ask whether the practice includes behavioral support, dietitian access, or group programming, and what happens to that support if medication coverage ends.

How Long Might Treatment Last, and What Is the Plan for Weight Regain?

Obesity is treated as a chronic condition, and weight regain after discontinuation is common, which points toward long-term or indefinite use for many patients paired with sustained lifestyle change. That framing should be explicit before starting.

Questions for the prescriber:

• Is there a maintenance dose, and how would we identify it?
• What is the plan if my weight plateaus well short of my goal?
• If I need to stop for cost, supply, or side effect reasons, how would we manage that transition?
• When would you refer me to an obesity medicine specialist or discuss bariatric surgery?
• Do other weight loss medications, including phentermine or orlistat products such as Alli, fit as alternatives or adjuncts in my case?

Ask what monitoring continues once weight stabilizes, including which labs get repeated and how often.

Preparing for an Informed Clinician Conversation

Walking into an appointment with written questions and a complete medication list changes what a clinician can accomplish in the visit. The territories worth covering are candidacy and history, contraindications, baseline labs, coverage and cost, and the long-term plan for side effects, muscle preservation, and maintenance.

Medical supervision is the through-line. Decisions about whether to start, which medication to use, how to escalate, when to pause, and whether to stop belong to a licensed prescriber who knows the full history, not to a checklist or a subscription platform.

Weight management with these drugs works alongside lifestyle changes rather than replacing them, and the protein, resistance training, and follow-up components deserve the same attention as the prescription itself.

This article is educational and does not constitute medical advice. Anyone considering a GLP-1 medication should discuss their individual health history, medications, and risks with a licensed clinician.

Frequently Asked Questions

What are the most important questions to ask before starting a GLP-1 medication?

The highest-value questions cover candidacy based on BMI and health conditions, contraindications including family history of medullary thyroid cancer or MEN2, which baseline labs and medication adjustments are needed, total out-of-pocket cost after insurance, and the plan for side effects and long-term use. Bringing every current prescription and supplement to the visit lets the clinician flag interactions on the spot.

Can I qualify for GLP-1 weight loss treatment if I do not have diabetes?

Yes. Candidacy for weight management is typically based on a BMI of 30 or higher, or a BMI of 27 and above with a weight-related condition such as high blood pressure, high cholesterol, fatty liver, or sleep apnea. Type 2 diabetes affects which medication and brand a clinician selects and often influences insurance coverage.

How much weight can people realistically lose on GLP-1 medications?

Average weight loss across this drug class ranges from 5.3% to 17.8% of body weight, with some patients losing more than 30%. Individual response varies substantially, so ask the prescriber what range applies to the specific medication and what timeline would signal a poor response.

How long do people usually take GLP-1 medications for weight loss?

Many patients remain on treatment long term, because obesity is treated as a chronic condition and weight regain after stopping is common. Discuss maintenance dosing, what monitoring continues after weight stabilizes, and how a transition off medication would be handled if cost or supply changes.

What should I ask about GLP-1 side effects and warning signs?

Ask which side effects to expect in the first weeks and after each dose increase, what home strategies help with nausea and constipation, and which symptoms require a same-day call. Severe abdominal pain, inability to keep fluids down, signs of hypoglycemia, and allergic reaction symptoms all warrant prompt medical attention.